BCTX
Income statement / Annual
Last year (2025), BriaCell Therapeutics Corp's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, BriaCell Therapeutics Corp's net income was -$36.49 M.
See BriaCell Therapeutics Corp,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
07/31/2025 |
07/31/2024 |
07/31/2023 |
07/31/2022 |
07/31/2021 |
07/31/2020 |
07/31/2019 |
07/31/2018 |
07/31/2017 |
07/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$147.89 K
|
$82.57 K
|
$15.53 K
|
$15.14 K
|
$15.58 K
|
$18.74 K
|
$18.83 K
|
$16.88 K
|
$289.71
|
$1.80 K
|
| Gross Profit |
-$147.89 K
|
-$82.57 K
|
-$15.53 K
|
-$15.14 K
|
-$15.58 K
|
-$18.74 K
|
-$18.83 K
|
-$16.88 K
|
-$289.00
|
-$1.80 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$29.50 M
|
$27.19 M
|
$20.48 M
|
$10.29 M
|
$2.53 M
|
$2.98 M
|
$4.94 M
|
$3.11 M
|
$2.12 M
|
$952.15 K
|
| General & Administrative Expenses |
$5.93 M
|
$6.15 M
|
$10.60 M
|
$9.32 M
|
$6.19 M
|
$1.50 M
|
$1.32 M
|
$1.37 M
|
$808.11 K
|
$577.11 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$561.16 K
|
$315.24 K
|
$762.50 K
|
| Selling, General & Administrative Expenses |
$8.08 M
|
$6.15 M
|
$10.60 M
|
$9.32 M
|
$6.19 M
|
$1.84 M
|
$1.29 M
|
$1.85 M
|
$1.09 M
|
$1.24 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$3.17 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$37.58 M
|
$33.34 M
|
$31.08 M
|
$19.61 M
|
$8.72 M
|
$4.82 M
|
$6.23 M
|
$4.96 M
|
$3.21 M
|
$2.19 M
|
| Cost And Expenses |
$37.73 M
|
$33.34 M
|
$31.08 M
|
$19.61 M
|
$8.72 M
|
$4.84 M
|
$6.25 M
|
$4.97 M
|
$3.21 M
|
$2.19 M
|
| Interest Income |
$166.38 K
|
$283.61 K
|
$1.20 M
|
$173.86 K
|
$4.02 K
|
$0.00
|
$12.06 K
|
$15.98 K
|
$6.42 K
|
$4.77 K
|
| Interest Expense |
$51.29 K
|
$0.00
|
$0.00
|
$1.24 K
|
$100.22 K
|
$36.20 K
|
$31.47 K
|
$20.34 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$147.89 K
|
$83.93 K
|
$20.39 K
|
$19.59 K
|
$19.07 K
|
$18.74 K
|
$18.83 K
|
$16.88 K
|
$289.71
|
$1.80 K
|
| EBITDA |
-$37.58 M |
-$4.85 M |
-$31.06 M |
-$34.40 M |
-$17.15 M |
-$4.82 M |
-$5.77 M |
-$5.37 M |
-$3.22 M |
-$2.23 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$899.68 K
|
$28.41 M
|
$3.97 M
|
-$14.81 M
|
-$8.55 M
|
-$113.98 K
|
$434.78 K
|
-$435.76 K
|
-$2.48 K
|
-$37.87 K
|
| Income Before Tax |
-$36.83 M
|
-$4.93 M
|
-$27.11 M
|
-$34.42 M
|
-$17.27 M
|
-$5.39 M
|
-$5.82 M
|
-$5.41 M
|
-$3.22 M
|
-$2.23 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$36.49 M
|
-$4.79 M
|
-$27.11 M
|
-$34.42 M
|
-$17.27 M
|
-$4.94 M
|
-$5.82 M
|
-$5.41 M
|
-$3.22 M
|
-$2.23 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-62.6 |
-43.01 |
-192.55 |
-257.58 |
-13.5 |
-5.64 |
-1505.3 |
-1798.34 |
-1348.63 |
-1360.3 |
| EPS Diluted |
-62.6 |
-43.01 |
-195 |
-259.5 |
-13.5 |
-5.64 |
-1505.3 |
-1798.34 |
-1348.63 |
-1360.3 |
| Weighted Average Shares Out |
$1.88 M
|
$1.10 M
|
$1.04 M
|
$1.03 M
|
$301.31 K
|
$47.59 K
|
$38.64 K
|
$28.52 K
|
$22.65 K
|
$19.23 K
|
| Weighted Average Shares Out Diluted |
$1.88 M
|
$1.10 M
|
$1.04 M
|
$1.03 M
|
$301.31 K
|
$47.59 K
|
$38.64 K
|
$28.52 K
|
$22.65 K
|
$19.23 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
